Focuses on rare disease diagnostics and genetic testing, providing insights for patients and pharmaceutical companies.
Centogene N.V., alongside its subsidiaries, specializes in rare diseases, leveraging clinical and genetic data to provide actionable insights for patients, physicians, and pharmaceutical firms globally. Structured into three segments Pharmaceutical, Diagnostics, and COVID-19 testing the company operates a rare disease platform that integrates epidemiological, phenotypic, and genetic data. This platform enhances the identification and monitoring of rare hereditary conditions, facilitating the development of orphan drugs.
Centogene offers a spectrum of services including target discovery, early patient recruitment, epidemiological insights, biomarker identification, and patient monitoring. It also provides genetic sequencing and diagnostics directly to physicians, laborathories, hospitals, and via distribution channels. Additionally, the company provides COVID-19 testing solutions encompassing PCR and antigen testing services.
Established in 2006 and headquartered in Rostock, Germany, Centogene collaborates with industry leaders such as Shire International GmbH, Pfizer Inc., Takeda Pharmaceutical Company Limited, and others. These partnerships underscore Centogene's commitment to advancing rare disease research and improving diagnostic capabilities worldwide.